Aitia is the leader in the development and application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs in neurodegenerative disorders, oncology, and immunology.  By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer, with several more in development. Aitia’s partners include six of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.

Aitia

In the aftermath of the JP Morgan conference, articles continue to surface about the dominated role of AI and the spotlight it took this year, marking a notable shift in focus for biopharma.

🆕 Read what leaders and experts had to say about the impact of AI in biopharma in this recent STAT article: https://lnkd.in/eKBkQ_CM

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery #CausalAI #GenerativeAI
Casey Ross

As JP Morgan conference fades into the rearview, the resonance of AI-Based Drug Discovery disrupting R&D grows louder. Throwback to our latest collaboration with Servier on Parkinson's Disease. 

Read the details in this press release if you haven't already: https://lnkd.in/eZziUqYK

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery #ParkinsonsDisease #movedbyyou
Ross Jeggo, Jean-Michel Gries

👋 We are pleased to announce our new collaboration with Aitia focused on Parkinson’s disease.

This collaboration illustrates our #Servier2030 ambition to be a focused and innovative player in neuroscience. 

According to Ross Jeggo, Global Head of Neuroscience and Immuno-inflammation Therapeutic Area in the Research and Development department at Servier, 🗣 “This new collaboration with Aitia highlights Servier’s ambition to potentially provide innovative solutions to patients with high unmet medical needs.”

Congratulations 👏 to the teams who contribute to the success of this collaboration.

#DrugDiscovery #innovation #neuroscience #ParkinsonsDisease #GeminiDigitalTwins #Gemini #MovedByYou

We are delighted to announce the extension of our collaboration with Servier into the realm of Parkinson's Disease. This new venture complements our ongoing partnerships focused on pancreatic cancer and multiple myeloma. 

Further details in the press release: https://lnkd.in/eZziUqYK

If you are interested in exploring our research and collaboration initiatives in neuroscience, make sure to connect with our partnering team at J.P. Morgan  Conference this week. 

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery #ParkinsonsDisease #movedbyyou #Servier

We’re excited to come together with the healthcare industry next week in San Francisco at #JPM24.

Make sure to reach out to our partnering team to learn more about our latest work and how we can join forces to discover novel targets and collaborate in drug simulations by leveraging the power of Gemini Digital Twins.

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery

As the holiday cheer winds down, we are gearing up for the much-anticipated J.P. Morgan Healthcare Conference just days away!

If you're attending the Biotech Showcase or any of the other biotech/life science conferences and investment summits next week, make sure to connect with  Aitia Team! We're San Francisco-bound, all set to launch into an amazing 2024.

https://lnkd.in/eN-g4Qju

#JPM24 #Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery
Colin Hill, Jean-Michel Gries

🎄Wishing you a happy holiday season and great success in the year to come! Season's greetings from the very merry #ATeam at Aitia ❄️

We are excited to announce the official launch of our new website! 

As a leading AI-enabled biotech company, our mission is to revolutionize drug discovery, challenging the traditional methods and pushing the boundaries of innovation.
 
🌐 Visit Aitiabio.com to learn more about our vision, approach, and people!

#Aitia #ATeam #GeminiDigitalTwins #Gemini #drugdiscovery

As we prepare to wrap up another exciting year for Aitia, we're eagerly looking forward to a bustling 2024. For now, we're gearing up for the J.P. Morgan conference, where our CEO Colin Hill and our President Jean-Michel Gries will be in attendance. Be sure to connect with them and request a meeting through the BIO partnering platform.

➡️ https://lnkd.in/dWvgeYi8

#JPM24 #Aitia #ATeam #DrugDiscovery #Gemini #GeminiDigitalTwins

What if an AI-based technology existed that could help treat pancreatic cancer?

📢 Spotlight on our collaboration with Servier to discover and simulate drugs in Pancreatic Cancer and gain deeper insights into the underlying mechanisms driving this complex disease to accelerate the discovery of new therapies for people living with pancreatic cancer.

Thank you Servier for this spotlight, we cherish our partnership and  we’re proud to be leading the charge against one of the cancers with the poorest prognosis!

➡️ Read what Servier had to say about his “Partner of Choice” in this article: https://lnkd.in/gWutbQFX

#PartnerOfChoice #Servier #Aitia #ATeam #Gemini #GeminiDigitalTwins #drugdiscovery 
Colin Hill, Fabien Schmidlin

Aitia is a leading AI-enabled biotech company focused on leveraging multi-omic patient data, high-performance computing, and causal AI to pioneer solutions in drug discovery and development.

COM:AITIABIO

Aitia

Filings Not Available